Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person nintedanib [cytosol]
| Class:Id | ChemicalDrug:9616923 |
|---|---|
| _displayName | nintedanib [cytosol] |
| _timestamp | 2018-12-12 00:29:46 |
| compartment | [Compartment:70101] cytosol |
| created | [InstanceEdit:9616924] Rothfels, Karen, 2018-08-15 |
| crossReference | [DatabaseIdentifier:9627979] ChEBI:85164 |
| disease | [Disease:1500689] cancer |
| modified | [InstanceEdit:9617179] Rothfels, Karen, 2018-08-17 [InstanceEdit:9627975] Wu, G, 2018-11-05 [InstanceEdit:9631716] Wu, G, 2018-12-12 |
| name | nintedanib BIBF 1120 BIBF1120 BIBF-1120 methyl (3Z)-3-((4-{methyl((4-methylpiperazin-1-yl)acetyl)amino}anilino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate |
| referenceEntity | [ReferenceTherapeutic:9603940] nintedanib [Guide to Pharmacology:5936] |
| stableIdentifier | [StableIdentifier:9616925] R-ALL-9616923.2 |
| (hasMember) | [DefinedSet:2077416] Tyrosine kinase inhibitors of FGFR3 mutants [cytosol] [DefinedSet:9674079] type II PDGFR-binding tyrosine kinase inhibitors [cytosol] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by nintedanib [cytosol] (9616923)
